Janssen licensed Darzalex from Denmark-based Genmab A/S in 2012. While the companies have enjoyed the regulatory success of Darzalex, they have gone into arbitration over royalties related to sales of the medication. When the two companies went into arbitration last year, Genmab said it is entitled to royalties from the marketing of the drug for both the intravenous form of Darzalex, and Darzalex Faspro for subcutaneous administration.